Ranibizumab · intravitreal injection
Injections & Implants
Approved uses
Neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization
0.5 mg (0.05 mL of the 10 mg/mL strength) intravitreally once a month; for myopic CNV, up to three months with retreatment as needed
The higher of the two strengths; myopic CNV is the only one with a defined stopping point
Diabetic macular edema and diabetic retinopathy
0.3 mg (0.05 mL of the 6 mg/mL strength) intravitreally once a month
The diabetic indications use the LOWER strength, 0.3 mg rather than 0.5 mg, at the same 0.05 mL volume
Contraindications
- Ocular or periocular infections
- Known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS (hypersensitivity reactions may manifest as severe intraocular inflammation)
Intravitreal injection, single-dose prefilled syringe delivering 0.05 mL: 0.5 mg (10 mg/mL) and 0.3 mg (6 mg/mL).
Ranibizumab binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF 110. VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and is thought to contribute to pathophysiology of neovascular AMD, mCNV, DR, DME and macular edema following RVO. The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.
Warnings & Precautions
- Endophthalmitis and retinal detachments: Intravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis and retinal detachments. Always use proper aseptic injection technique, and monitor patients following the injection to permit early treatment should an infection occur.
- Increases in intraocular pressure: Increases in intraocular pressure have been noted both pre-injection and post-injection (at 60 minutes). Monitor intraocular pressure prior to and following intravitreal injection and manage appropriately.
- Thromboembolic events: Although there was a low rate of arterial thromboembolic events (ATEs) in the LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).
- Fatal events in patients with DME and DR at baseline: In a pooled analysis of Studies D-1 and D-2, fatalities in the first 2 years occurred in 4.4% of patients treated with 0.5 mg LUCENTIS, 2.8% of patients treated with 0.3 mg LUCENTIS, and 1.2% of control patients. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship to intravitreal use of VEGF inhibitors cannot be excluded.
- Retinal vasculitis with or without occlusion: Retinal vasculitis with or without occlusion, typically in the presence of preexisting intraocular inflammation or post-treatment with other intravitreal agents, has been reported with the use of LUCENTIS. Discontinue treatment in patients who develop these events, and instruct patients to report any change in vision without delay.
Common Side Effects
The most common adverse reactions (reported more frequently in LUCENTIS-treated subjects than control subjects) are conjunctival hemorrhage, eye pain, vitreous floaters, and increased IOP.
Pregnancy: There are no adequate and well-controlled studies in pregnant women. Ranibizumab given to pregnant monkeys throughout the period of organogenesis resulted in a low incidence of skeletal abnormalities at intravitreal doses 13-times the predicted human exposure after a single eye treatment at the recommended clinical dose. Based on the anti-VEGF mechanism of action, treatment with LUCENTIS may pose a risk to human embryofetal development, and it should be given to a pregnant woman only if clearly needed.
Lactation: There are no data on the presence of ranibizumab in human milk, the effects on the breastfed infant, or the effects on milk production. Caution should be exercised when LUCENTIS is administered to a nursing woman.
The safety and effectiveness of LUCENTIS in pediatric patients have not been established.